铁剂治疗腹膜透析患者肾性贫血的临床研究  

CLINICAL STUDY OF IRON THERAPY IN PERITONEAL DIALYSIS PATIENTS WITH RENAL ANEMIA

作　　者：刘远浩[1] 

机构地区：[1]中山市人民医院,广东中山528403

出　　处：《现代医院》2013年第3期19-21,共3页Modern Hospitals

摘　　要：目的观察口服多糖铁复合物与静脉蔗糖铁配合促红细胞生成素(EPO)治疗维持性腹膜透析患者肾性贫血的有效性和安全性。方法选择我院维持性腹膜透析(CAPD)患者48例,按入院顺序查表随机分为口服组和静脉组各24例,总疗程为12周。比较治疗前、后患者的血红蛋白(Hb)、红细胞压积(Hct)、血清铁(SFe)、血清铁蛋白(SF)、血清转铁蛋白饱和度(TSAT)、EPO用量的变化。结果治疗后第6、12周两组患者血红蛋白、红细胞压积、血清铁、血清铁蛋白和转铁蛋白饱和度水平比治疗前提高,但静脉组比口服组指标升高更明显,差异有统计学意义(p<0.05)。治疗后两组患者EPO用量较治疗前均有所减少,但静脉组减少更加明显(p<0.05)。结论静脉用蔗糖铁可有效纠正维持性腹膜透析患者肾性贫血的铁缺乏,有效改善贫血,安全性好。Objective To observe the efficacy and safety of oral polysaccharide iron complex or intravenous iron sucrose in erythropoietin - treated maintenance peritoneal dialysis patients with renal anemia. Methods 48 maintenance peritoneal dialysis patients of our hospital were averagely divided into two groups randomly and treated with oral polysaccharide iron complex or intravenous iron sucrose. The total course of treatment is 12 weeks. The levels of hemoglobin（ Hb）, hemotocrit （ Hct）, serum ferrum （ SFe）, serum ferritin （ SF）, transferring saturation （TSAT）, erythropoietin dosage were compared before treatment and after treatment. Results After treatment sixth, twelfth weeks the patient＇s level of Hb, Hct, SFe, SF, TSAT were increased in both groups. While intravenous iron group was significantly higher than oral iron group （p 〈 0.05 ）. Doses of erythropoietin were decreased in both groups. Butthe intravenous group was significantly lower than oral group （p 〈 0. 05 ）. Conclusion Intravenous iron sucrose is effective and safe in correcting iron deficiency and improving anemia in maintenance peritoneal dialysis patients with re- nal anemia.

关 键 词：蔗糖铁 肾性贫血维持性腹膜透析 

分 类 号：R695.05[医药卫生—泌尿科学]